Press Releases

< 2022 >

Filter:

May 24, 2022
Genocea Announces Wind Down of Operations and Delisting From NASDAQ
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company...
April 28, 2022
Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical compa...
April 8, 2022
Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022
     GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with...
April 4, 2022
Genocea Biosciences to Host Investor Webinar
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical compa...
March 14, 2022
Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference
CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical compa...
March 10, 2022
Genocea Provides Fourth Quarter 2021 Corporate Update
Initial GEN-011 clinical trial data to be presented at AACR Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., Marc...
March 8, 2022
Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting
Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea’s neoantigen-targeted periphe...
March 7, 2022
John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Directors
CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical compa...
March 3, 2022
Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical compa...
February 10, 2022
Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical compan...
January 5, 2022
Genocea to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical compan...
January 4, 2022
Genocea Biosciences Provides Corporate Update
Enters into Inhibigen™ R&amp;D collaboration and option agreement with Janssen Reports progress on the GEN-011 TiTAN ™ t...